108 related articles for article (PubMed ID: 24485335)
21. TP63-TRIM29 axis regulates enhancer methylation and chromosomal instability in prostate cancer.
Sultanov R; Mulyukina A; Zubkova O; Fedoseeva A; Bogomazova A; Klimina K; Larin A; Zatsepin T; Prikazchikova T; Lukina M; Bogomiakova M; Sharova E; Generozov E; Lagarkova M; Arapidi G
Epigenetics Chromatin; 2024 Mar; 17(1):6. PubMed ID: 38481282
[TBL] [Abstract][Full Text] [Related]
22. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical pitfalls in prostate pathology.
Brimo F; Epstein JI
Hum Pathol; 2012 Mar; 43(3):313-24. PubMed ID: 22325142
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
Humphrey PA
J Clin Pathol; 2007 Jan; 60(1):35-42. PubMed ID: 17213347
[TBL] [Abstract][Full Text] [Related]
25. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
26. Identification of PCAG1 as a novel prostate cancer-associated gene.
Lai Y; Yu Z; Wang Y; Ye J
Mol Med Rep; 2013 Mar; 7(3):755-60. PubMed ID: 23292432
[TBL] [Abstract][Full Text] [Related]
27. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
[TBL] [Abstract][Full Text] [Related]
30. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
31. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
[TBL] [Abstract][Full Text] [Related]
32. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer.
Padmanabhan V; Callas P; Philips G; Trainer TD; Beatty BG
J Clin Pathol; 2004 Oct; 57(10):1057-62. PubMed ID: 15452160
[TBL] [Abstract][Full Text] [Related]
33. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
35. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
36. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.
Upadhyay J; Shekarriz B; Nemeth JA; Dong Z; Cummings GD; Fridman R; Sakr W; Grignon DJ; Cher ML
Clin Cancer Res; 1999 Dec; 5(12):4105-10. PubMed ID: 10632347
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
Varma M; Jasani B
Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
[TBL] [Abstract][Full Text] [Related]
38. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
39. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
40. TRIM29 negatively regulates p53 via inhibition of Tip60.
Sho T; Tsukiyama T; Sato T; Kondo T; Cheng J; Saku T; Asaka M; Hatakeyama S
Biochim Biophys Acta; 2011 Jun; 1813(6):1245-53. PubMed ID: 21463657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
